



Altimune to Announce Year End 2019 Financial Results on March 27

March 25, 2020

GAITHERSBURG, Md., March 25, 2020 (GLOBE NEWSWIRE) -- Altimune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that it will report financial results for the year ended December 31, 2019 and host a conference call on Friday, March 27, 2020.

Conference Call Details

Date: Friday, March 27
Time: 8:30 am Eastern Time
Domestic: 877-423-9813
International: 201-689-8573
Conference ID: 13701071
Webcast: <http://public.viavid.com/index.php?id=138792>

About Altimune

Altimune is a clinical stage biopharmaceutical company focused on developing treatments for liver disease, immune modulating therapies and vaccines. Our diverse pipeline of product candidates includes next generation peptide therapeutics for NASH (ALT-801) and chronic hepatitis B (HepTcell™), conjugated immunostimulants for the treatment of cancer (ALT-702) and intranasal vaccines (NasoVAX™, NasoShield™ and AdCOVID™). For more information on Altimune, please visit www.altimmune.com.

Contacts:

Will Brown	Ashley R. Robinson
Chief Financial Officer	LifeSci Advisors, LLC
Phone: 240-654-1450	617-430-7577
wbrown@altimmune.com	arr@lifesciadvisors.com



Source: Altimune, Inc.